Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Gaw

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Controlled Clinical Trials|December 31, 2002
Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trialJerry Avorn, Josh Benner, Ian Ford, et al.
Kidney International. Supplement|November 27, 2008
Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFASTLuis M Blanco-Colio, Jose L Martín-Ventura, Eduardo de Teresa, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 21, 2006
Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFASTLuis M Blanco-Colio, Jose L Martín-Ventura, Eduardo de Teresa, et al.
Atherosclerosis|December 17, 2009
Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Muriel J Caslake, Chris J Packard, Michele Robertson, et al.
Circulation|July 16, 2003
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention StudyNaveed Sattar, Allan Gaw, Olga Scherbakova, et al.
European Journal of Pharmacology|April 1, 2008
Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular riskLuis M Blanco-Colio, Jose L Martín-Ventura, Carmen Gómez-Guerrero, et al.
Journal of Clinical Pharmacology|May 26, 2011
Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) studyMilan Gupta, Pierre Martineau, Thang Tran, et al.
Circulation|January 28, 2004
Metabolic syndrome and diabetes mellitusW E Feeman, Naveed Sattar, Denis St J OReilly, et al.
BMC Geriatrics|February 24, 2011
Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Dilys J Freeman, Michele Robertson, E Ann Brown, et al.
Current Controlled Trials in Cardiovascular Medicine|July 5, 2002
A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline CharacteristicsIan Ford, Gerard Jan Blauw, Michael B Murphy, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Controlled Clinical Trials|December 31, 2002
Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trialJerry Avorn, Josh Benner, Ian Ford, et al.
Kidney International. Supplement|November 27, 2008
Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFASTLuis M Blanco-Colio, Jose L Martín-Ventura, Eduardo de Teresa, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 21, 2006
Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFASTLuis M Blanco-Colio, Jose L Martín-Ventura, Eduardo de Teresa, et al.
Atherosclerosis|December 17, 2009
Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Muriel J Caslake, Chris J Packard, Michele Robertson, et al.
Circulation|July 16, 2003
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention StudyNaveed Sattar, Allan Gaw, Olga Scherbakova, et al.
European Journal of Pharmacology|April 1, 2008
Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular riskLuis M Blanco-Colio, Jose L Martín-Ventura, Carmen Gómez-Guerrero, et al.
Journal of Clinical Pharmacology|May 26, 2011
Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) studyMilan Gupta, Pierre Martineau, Thang Tran, et al.
Circulation|January 28, 2004
Metabolic syndrome and diabetes mellitusW E Feeman, Naveed Sattar, Denis St J OReilly, et al.
BMC Geriatrics|February 24, 2011
Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Dilys J Freeman, Michele Robertson, E Ann Brown, et al.
Current Controlled Trials in Cardiovascular Medicine|July 5, 2002
A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline CharacteristicsIan Ford, Gerard Jan Blauw, Michael B Murphy, et al.
Pageof 5